Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients
复制标题
DOI：
10.1002/hep.24624
复制
发表时间：
2012-01-01
期刊：
影响因子：
13.5
通讯作者：
Elkashab, Magdy
中科院分区：
文献类型：
--
作者：
Myers, Robert P.;Pomier-Layrargues, Gilles;Elkashab, Magdy
通过瞬时弹性成像（TE，FibroScan）进行的肝硬度测量（LSM）失败和不可靠的结果分别发生在约5%和15%的患者中，主要是由于肥胖。在这项多中心研究中，我们评估了新型FibroScan XL探头在276例慢性肝病（42%病毒性肝炎，46%非酒精性脂肪性肝病[NAFLD]）和体重指数（BMI）=28 kg/m2的患者中的可行性和性能。患者接受了肝活检，并使用标准M和XL探头进行了TE。TE失败定义为无有效LSM，不可靠检查定义为30%或成功率
Failure of liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) and unreliable results occur in approximate to 5% and 15% of patients, respectively, mainly due to obesity. In this multicenter study, we evaluated the feasibility and performance of the novel FibroScan XL probe in 276 patients with chronic liver disease (42% viral hepatitis, 46% nonalcoholic fatty liver disease [NAFLD]) and a body mass index (BMI) =28 kg/m2. Patients underwent liver biopsy and TE with the standard M and XL probes. TE failure was defined as no valid LSMs and unreliable examinations as 30% or success rate